Screener
Vor Biopharma VOR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $169,873 | $396,486 |
| Marketable securities | 321,652 | 58,722 |
| Prepaid expenses | 6,394 | 1,152 |
| Other current assets | 2,859 | 1,745 |
| Total current assets | 500,778 | 458,105 |
| Restricted cash | 168 | 168 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's cash & equivalents?
- Vor Biopharma (VOR) reported cash & equivalents of $169.87M in Q1 2026.
- How has Vor Biopharma's cash & equivalents changed year-over-year?
- Vor Biopharma's cash & equivalents increased by 239.4% year-over-year, from $50.05M to $169.87M.
- What is the long-term trend for Vor Biopharma's cash & equivalents?
- Over 5 years (2020 to 2025), Vor Biopharma's cash & equivalents has grown at a 52.2% compound annual growth rate (CAGR), from $48.54M to $396.49M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Vor Biopharma's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude